Mark C. McKenna

Bio:

Mark C. McKenna is a luminary biotech entrepreneur, executive and director with a track-record of delivering exceptional results for investors and patients. He served as Chairman, President and CEO of Prometheus Biosciences from 2019 through the company’s acquisition by Merck for $10.8B in June 2023. Under his leadership, Prometheus raised more than $1B in private and public financing, was the top-performing biotech IPO of 2021, created the first precision therapeutics for immune-mediated diseases and delivered industry-best results in Phase 2. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of Salix Pharmaceuticals, where he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2B while enhancing operating margins. Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he significantly grew revenue by 22% CAGR in an otherwise flat market. He began his career at Johnson & Johnson. Mr. McKenna currently also serves as the Managing Director of McKenna Capital Partners, Chairman of Apogee Therapeutics, Inc. and sits on the board of Spyre Therapeutics, Inc. Mr. McKenna was Ernst & Young Entrepreneur of the Year in 2023 and holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University.